Interaction between valproate and meropenem: A retrospective study

Annals of Pharmacotherapy

Volumn 41, Issue 7-8, 2007, Pages 1130-1136

  Spriet, Isabel ^a   Goyens, Jo ^a   Meersseman, Wouter ^a   Wilmer, Alexander ^a   Willems, Ludo ^a   Van Paesschen, Wim ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Epilepsy; Interaction; Meropenem; Valproate

Indexed keywords

CARBAMAZEPINE; CLOBAZAM; ERTAPENEM; ETIRACETAM; IMIPENEM; LAMOTRIGINE; LORAZEPAM; MEROPENEM; MIDAZOLAM; PANIPENEM; PHENOBARBITAL; PHENYTOIN; PROPOFOL; TOPIRAMATE; VALPROIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DETERIORATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG WITHDRAWAL; EEG ABNORMALITY; ELECTROCARDIOGRAM; EPILEPSY; FATALITY; FEMALE; HOSPITAL PATIENT; HUMAN; INFECTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; SCORING SYSTEM; SEIZURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THIENAMYCINS; VALPROIC ACID;

EID: 34547221003     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K079     Document Type: Article

References (30)

1. Peters CN, Pohlmann-Eden B. Intravenous valproate as an innovative therapy in seizure emergency situations including status epilepticus - experience in 102 adult patients. Seizure 2005;14:164-9.
2. Nagai K, Shimizu T, Togo A, et al. Decrease in serum levels of valproic acid during treatment with a new carbapenem, panipenem/betamipron. J Antimicrob Chemother 1997;39:295-6.
3. De Turck BJ, Diltoer MW, Cornelis PJ, et al. Lowering of plasma valproic acid concentrations during concomitant therapy with meropenem and amikacin. J Antimicrob Chemother 1998;42:563-4.
4. Yamagata T, Momoi MY, Murai K, et al. Panipenem-betamipron and decreases in serum valproic acid concentration. Ther Drug Monit 1998;20:396-400.
5. Llinares-Tello F, Bosacoma-Ros N, Hernandez-Prats C, Climent-Grana E, Selva-Otaolaurruchi J, Ordovas-Baines JP. Pharmacokinetic interaction between valproic acid and carbapenem-like antibiotics: a discussion of three cases. Farm Hosp 2003;24:258-63.
6. Nacarkucuk E, Saglam H, Okan M. Meropenem decreases serum level of valproic acid. Pediatr Neurol 2004;31:232-4.
7. Clause D, Decleire PY, Vanbinst R, Soyer A, Hantson P. Pharmacokinetic interaction between valproic acid and meropenem. Intensive Care Med 2005;31:1293. Epub 14 Jun 2005.
8. Coves-Orts FJ, Borrás-Blasco J, Navarro-Ruiz A, Murcia-López A, Palacios-Ortega F. Acute seizures due to a probable interaction between valproic acid and meropenem. Ann Pharmacother 2005;39:533-7. Epub 8 Feb 2005. DOI 10.1345/aph.1E358
9. Lam F. Valproic acid taken with meropenem may result in seizures. The Brown University Psychopharmacology Update 2005;6:2-3.
10. Santucci M, Parmeggiani A, Riva R. Seizure worsening caused by decreased serum valproate during meropenem therapy. J Child Neurol 2005;20:456-7.
11. Perea-Falomir M, Roura-Poch P, Higueruelo-Demason S, Garcia-Gil VJ. Pharmacokinetic interaction between valproic acid and meropenem. Farm Hosp 2006;30:316-7.
12. Cabanes-Mariscal MA, Sanchez-Lopez P, Herranz-Alvarez P, Merino-Chamorro G. Pharmacokinetic interaction between valproic acid and ertapenem. Farm Hosp 2006;30:313-5.
13. Fudio S, Carcas A, Pinana E, Ortega R. Epileptic seizures caused by low valproic acid concentrations from an interaction with meropenem. J Clin Pharm Ther 2006;31:393-6.
14. Spriet I, Meersseman W, De Troy E, Wilmer A, Casteels M, Willems L. Meropenem-valproic acid interaction in patients with cefepime-associated status epilepticus. Am J Health Syst Pharm 2007;64:54-8.
15. Mouton JW, Van Den Anker JN. Meropenem clinical pharmacokinetics. Clin Pharmacokinet 1995;28:275-89.
16. Bax RP, Bastain W, Featherstone A, et al. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother 1989;24:311-20.
17. Vree TB, Van Der Kleijn E. Pharmacokinetics and renal excretion of 2-n-propylpentanoate (Depakine) in man, dog and rhesus monkey. Pharm Weekbl 1977;112:290-2.
18. Dickinson RG, Harland RC, Robert DH, et al. Disposition of valproic acid in the rat: dose-dependent metabolism, distribution, enterohepatic recirculation and choleretic effect. J Pharmacol Exp Ther 1979;211:583-95.
19. Zaccara G. Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 1988;15:367-89.
20. Nakajima Y, Mizobuchi M, Nakamura M. Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats. Drug Metab Disp 2004;32:1383-91.
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-47.
22. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:489-501.
23. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-99.
24. Lowenstein DH, Bleck T, Macdonald RL. It's time to revise the definition of status epilepticus. Epilepsia 1999;40:120-2.
25. Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41:674-80. Epub 27 Mar 2007. DOI 10.1345/aph.1H423
26. Package insert. Meronem (meropenem). Brussels, Belgium: AstraZeneca, June 2006.
27. Norrby SR. Carbapenems in serious infections: a risk-benefit assessment. Drug Saf 2000;22:191-4.
28. Cunha BA. Meropenem in elderly and renally impaired patients. Int J Antimicrob Agents 1999;11:167-77.
29. Pisani F. Influence of co-medication on the metabolism of valproate. Pharm Weekbl Sci 1992;14:108-13.
30. Perucca E. Clinically relevant drug interactions with anti-epileptic drugs. Br J Clin Pharmacol 2006;61:246-55.